Current progress in car-t cell therapy for solid tumors

Shuo Ma, Xinchun Li, Xinyue Wang, Liang Cheng, Zhong Li, Changzheng Zhang, Zhenlong Ye, Qijun Qian

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US. Despite the progresses made in treating hematological malignancies, challenges still remain for use of CAR-T cell therapy to treat solid tumors. In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors. To further understand the current status and trend for developing CAR-T cell based therapies for various solid tumors, this review emphasizes on CAR-T techniques, current obstacles, and strategies for application, as well as necessary companion diagnostics for treatment of solid tumors with CAR-T cells.

Original languageEnglish (US)
Pages (from-to)2548-2560
Number of pages13
JournalInternational Journal of Biological Sciences
Issue number12
StatePublished - 2019


  • CAR-T cells
  • CTC
  • Chimeric antigen receptor
  • Companion diagnostics
  • Solid tumors

ASJC Scopus subject areas

  • Ecology, Evolution, Behavior and Systematics
  • Applied Microbiology and Biotechnology
  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Current progress in car-t cell therapy for solid tumors'. Together they form a unique fingerprint.

Cite this